www.calithera.com Open in urlscan Pro
35.196.172.97  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Careers
 * News
 * Publications
 * Contact Us
 * 
 * 

MENU
Close x
 * Company
   About Us Management Team Board of Directors Collaborations Careers Contact Us
 * Therapeutic Areas
   Oncology Publications
 * Programs
   Pipeline mTORC1/2 inhibitor Sapanisertib SYK Inhibitor Mivavotinib
   Preclinical Programs
 * Clinical Trials
   Clinical Trials Overview Expanded Access
 * Investors
   Corporate Profile Press Releases Event & Presentations Stock Information
   Financial Information
   Overview SEC Filings Ownership Summary
   Analyst Coverage Corporate Governance
   Highlights Board of Directors Management Team Committee Composition
   Shareholder Services
   Investor FAQs E-mail Alerts
   Proxy & Annual Report Contact Us

 * Careers
 * News
 * Publications
 * Contact Us
 * 
 * 


TARGETING CANCER, DIFFERENTLY.

Our biomarker-driven approach will
redefine cancer treatment.

Learn More


TARGETING CANCER, DIFFERENTLY.

Our biomarker-driven approach will
redefine cancer treatment.

Learn More


TARGETING CANCER, DIFFERENTLY.

Our biomarker-driven approach will
redefine cancer treatment.

Learn More



DEVELOPMENT PIPELINE

Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical
company developing targeted therapies to redefine treatment for
biomarker-specific patient populations.

Learn More


DEVELOPMENT PIPELINE

Calithera is a clinical-stage biopharmaceutical company pioneering the discovery
and development of targeted, small molecule therapies that disrupt cellular
metabolic pathways to preferentially block tumor cell growth and enhance
immune-cell activity.

Learn More

CULTURE

THERAPEUTIC AREAS


RECENT NEWS

November 14, 2022


CALITHERA BIOSCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND BUSINESS
UPDATE

November 8, 2022


CALITHERA BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON MONDAY,
NOVEMBER 14, 2022

October 3, 2022


CALITHERA RECEIVES FDA FAST TRACK DESIGNATION FOR SAPANISERTIB FOR THE TREATMENT
OF NRF2-MUTATED SQUAMOUS LUNG CANCER

September 6, 2022


CALITHERA TO PRESENT AT THE H.C. WAINWRIGHT 24TH ANNUAL GLOBAL INVESTMENT
CONFERENCE

August 15, 2022


CALITHERA BIOSCIENCES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND RECENT
HIGHLIGHTS

View All
Company
 * About Us
 * Management Team
 * Board of Directors
 * Collaborations
 * Careers
 * Contact Us

Therapeutic Areas
 * Oncology
 * Publications

Programs
 * Pipeline
 * mTORC1/2 inhibitor Sapanisertib
 * SYK Inhibitor Mivavotinib
 * Preclinical Programs

Clinical Trials
 * Clinical Trial Overview
 * Expanded Access

Investors
 * Corporate Profile
 * Press Release
 * Events & Presentations
 * Stock Information
 * Financial Information
 * Analyst Coverage
 * Corporate Governance
 * Shareholder Services
 * Proxy & Annual Report
 * Contact Us

© 2022 Calithera Biosciences, Inc. All rights reserved.
ETHICS & COMPLIANCEPRIVACY POLICYLEGAL TERMS OF USE
 * Contact Us
 * News


CALITHERA® and the Calithera logos are trademarks or registered trademarks of
Calithera Biosciences, Inc.
CALITHERA® and the Calithera logos are trademarks or registered trademarks of
Calithera Biosciences, Inc.